Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential.

ABSTRACT: Myasthenia gravis (MG) is an autoimmune disease leading to varying degrees of skeletal muscle weakness. It is caused by specific antibodies directed against definite components in the postsynaptic membrane at the neuromuscular junction (NMJ), such as the acetylcholine receptor (AChR) and the muscle-specific kinase (MUSK) receptor. In clinical practice, MG patients may be classified into three main subgroups based on the occurrence of serum autoantibodies directed against AChR or MUSK receptor or antibody-negative. As the MG subgroups differ in terms of clinical characteristics, disease pathogenesis, prognosis, and response to therapies, they could benefit from targeted treatment as well as the detection of other possible disease biomarkers. We performed proteomics on plasma fractions enric

SUBMITTER: Lepedda AJ 

PROVIDER: S-EPMC6740073 | biostudies-literature | 2019 Jan-Dec

REPOSITORIES: biostudies-literature